ClinicalTrials.gg
RecruitingNCT04438889aMYELOIDrUpdated Apr 10, 2025

Austrian Myeloid Registry

An observational study in Myeloid Diseases, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Recruiting at 16 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Observational

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Study summary

The Austrian Myeloid Registry (aMYELOIDr) is a non-interventional study. It collects data from patients with the myeloid diseases, primarily myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).The aMYELOIDr is multi-center database collecting data at various sites in Austria and potentially also at other centers in other countries in future. The registry has an electronic case report form (eCRF), where all data is entered by clinical trial personnel and/or physicians. It is set up to collect real-world experience in the management of patients with these diseases in Austria.

02

Conditions studied

  • Myeloid Diseases

Keywords

  • MDS
  • CMML
  • AML
  • PMF
  • Austrian Myeloid Registry
03

In context

Lead sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie is the lead sponsor of 43 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with AML, MDS, CMML or PMF according to WHO 2016 diagnostic criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >17 years
  • Diagnosis of myeloid disease according to WHO 2016
  • Signed patient (IC)

Exclusion criteria

Exclusion Criteria:

  • Patient is unable or unwilling to sign IC
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • AML

    Patients with WHO 2016 diagnosis of AML

    Other: Non-interventional

  • MDS

    Patients with WHO 2016 diagnosis of MDS

    Other: Non-interventional

  • CMML

    Patients with WHO 2016 diagnosis of CMML

    Other: Non-interventional

  • PMF

    Patients with WHO 2016 diagnosis of PMF

    Other: Non-interventional

Interventions

  • OtherNon-interventional

    Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.

06

What researchers measure

Primary outcomes

  1. To assess the treatment patterns (therapeutic landscape) of patients with myeloid diseases.

    Due to the non-interventional nature of the aMYELOIDr, treatment indication, the decision to offer treatment, treatment choice, dose, schedule and dose reductions/escalations shall be exclusively based on the risk/benefit estimation of the treating physician. We recommend compliance current guidelines.

    Time frame: Through study completion, median expected within 100 months

Secondary outcomes

  1. Impact of front-line treatment on overall survival (OS)

    Time frame: Through study completion, median expected within 100 months

  2. Impact of number and choice of treatment lines on OS as of initial diagnosis and/or as of treatment start

    Time frame: Through study completion, median expected within 100 months

  3. Overall response rate (ORR)

    Response will be assessed according to current guidelines for the respective disease. Due to the non-interventional nature of the aMYELOIDr, timepoints and types of response assessment shall be exclusively based on the risk/benefit estimation of the treating physician. We recommend compliance current guidelines.

    Time frame: Through study completion, median expected within 100 months

  4. Event free survival (EFS)

    Events include treatment failure, progressive disease, relapse after CR/CRi, death from any cause. Patients lost to-follow-up or still alive ans without event will be censored at last follow-up date

    Time frame: Through study completion, median expected within 100 months

  5. AML transformation

    Time to transformation to AML for patients with a non-AML initial diagnosis

    Time frame: Through study completion, median expected within 100 months

  6. Treatment safety

    Investigators should report adverse reactions (for which a causal role of a medicine is suspected) to the concerned competent authorities following regulations in the current or future versions of Austrian legislation (Pharmakovigilanz-Verordnung 2013 (PhVO, Regulation on Pharmacovigilance), Österreichisches Arzneimittel Gesetz (AMG, Austrian Medicinal Products Act). Participation in this registry does not exempt the participating center from their legal reporting obligations. Documentation of causality, duration, frequency and severity of adverse events (AEs) according to Common Terminology Criteria for AE (CTCAE v.5).

    Time frame: Through study completion, median expected within 100 months

  7. Concomitant treatments

    Concomitant treatments (number of administration of e.g. prophylactic antibiotics, antivirals, antifungals)

    Time frame: Through study completion, median expected within 100 months

  8. Treatment characteristics

    Among others, the following treatment characteristics will be assessed for each treatment line: substance

    Time frame: Through study completion, median expected within 100 months

  9. Treatment characteristics

    Among others, the following treatment characteristics will be assessed for each treatment line: application date

    Time frame: Through study completion, median expected within 100 months

  10. Treatment characteristics

    Among others, the following treatment characteristics will be assessed for each treatment line: route

    Time frame: Through study completion, median expected within 100 months

  11. Treatment characteristics

    Among others, the following treatment characteristics will be assessed for each treatment line: dose

    Time frame: Through study completion, median expected within 100 months

  12. Treatment characteristics

    Among others, the following treatment characteristics will be assessed for each treatment line: inpatient or outpatient setting

    Time frame: Through study completion, median expected within 100 months

  13. Concomitant treatments best supportive care (BSC)

    Concomitant best supportive care (BSC) measures (e.g. number of transfusions, growth factors, iron chelators)

    Time frame: Through study completion, median expected within 100 months

  14. Quality of life assessment EQ-5D-5L (optional)

    EuroQol-5 Dimensions with 5 Levels. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

    Time frame: Through study completion, median expected within 100 months

  15. EORTC Quality of life assessment QLQ-C30 (optional)

    European Organisation for Research and Treatment of Cancer Quality of life 30-item questionnaire of cancer patients incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation anddiarrhoea) and perceived financial impact of the disease. It has four-point scale which are coded with "Not at all", "A little", "Quite a bit" and "Very much"

    Time frame: Through study completion, median expected within 100 months

Other outcomes

  1. Minimal residual disease

    Assess how many and which patients in Austria have minimal residual disease (MRD) assessments, assessed by which techniques and at which timepoints.

    Time frame: Through study completion, median expected within 100 months

  2. MRD-negativity on OS

    Assess the impact of MRD-negativity on OS. MRD assessment via flow-cytometry and polymerase chain reactions according to the current ELN guidelines 2017 shall be exclusively based on the risk/benefit estimation of the treating physician.

    Time frame: Through study completion, median expected within 100 months

  3. Prognostic and predictive markers

    Analyses of various factors known or thought to influence OS, ORR, EFS, PFS and time to next treatment in order to validate existing or establish novel prognostic and predictive markers

    Time frame: Through study completion, median expected within 100 months

07

Study locations

15 of 16 sites recruiting
  • LKH Feldkirch, Innere Medizin II, Interne E: Hämatologie und Onkologie
    Feldkirch, 6807, Austria
    Recruiting
    • Bernd Hartmann, MD · Principal investigator
  • KH der Barmherzigen Brüder, Innere Medizin I
    Graz, 8020, Austria
    Recruiting
    • Andrea Hammerl-Steiner, MD · Principal investigator
  • Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Hämatologie
    Graz, 8036, Austria
    Not yet recruiting
    • Armin Zebisch, MD · Principal investigator
  • Universitätsklinik Innsbruck, Univ.-Klinik für Innere Medizin V, Hämatologie und Onkologie
    Innsbruck, 6020, Austria
    Recruiting
    • Dominik Wolf, MD · Principal investigator
  • Universitätsklinikum Krems, Innere Medizin II Hämato-Onkologie
    Krems, 3500, Austria
    Recruiting
    • Martin Pecherstorfer, MD · Principal investigator
  • LKH Hochsteiermark, Abteilung für Hämato-Onkologie
    Leoben, 8700, Austria
    Recruiting
    • Angelika Pichler, MD · Principal investigator
  • Ordensklinikum Linz GmbH, Barmherzige Schwestern, Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie
    Linz, 4010, Austria
    Recruiting
    • Gregor Aschauer, MD · Principal investigator
  • Ordensklinikum Linz GmbH, Elisabethinen, I. Interne Abteilung Hämato-Onkologie
    Linz, 4020, Austria
    Recruiting
    • Sigrid Machherndl-Spandl, MD · Principal investigator
  • Kepler Universitätsklinikum Linz, Med. Campus III., Univ.-Klinik für Hämatologie und Internistische Onkologie
    Linz, 4021, Austria
    Recruiting
    • Clemens Schmitt, MD · Principal investigator
  • Universitätsklinik für Innere Med. III, PMU Salzburg
    Salzburg, 5020, Austria
    Recruiting
    • Lisa Pleyer, MD · Principal investigator
  • Universitätsklinikum St. Pölten, Klinische Abteilung für Innere Medizin 1
    St. Pölten, 3100, Austria
    Recruiting
    • Petra Pichler, MD · Principal investigator
  • Klinikum Steyr, Innere Medizin II
    Steyr, 4400, Austria
    Recruiting
    • Johannes Andel, MD · Principal investigator
  • Klinik Donaustadt: 2. Medizinische Abteilung
    Vienna, 1220, Austria
    Recruiting
    • Margarete Stampfl-Mattersberger, MD · Principal investigator
  • Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin IV
    Wels, 4600, Austria
    Recruiting
    • Sonja Heibl, MD · Principal investigator
  • Hanusch KH, 3. Med. Abteilung
    Wien, 1140, Austria
    Recruiting
    • Felix Keil, MD · Principal investigator
  • Klinik Ottakring, 1. Med. Abteilung
    Wien, 1160, Austria
    Recruiting
    • Martin Schreder, MD · Principal investigator
08

References and documents

Publications

  • Falantes J, Pleyer L, Thepot S, Almeida AM, Maurillo L, Martinez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martinez MP, Seegers V, Cortesao E, Foncillas MA, Gardin C, Montesinos P, Musto P, Fenaux P, Greil R, Sanz MA, Ramos F; European ALMA + Investigators. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). Leuk Lymphoma. 2018 May;59(5):1113-1120. doi: 10.1080/10428194.2017.1365854. Epub 2017 Aug 24. PubMed 28838276 ↗
  • Leisch M, Weiss L, Lindlbauer N, Jungbauer C, Egle A, Rohde E, Greil R, Grabmer C, Pleyer L. Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience. Leuk Res. 2017 Aug;59:12-19. doi: 10.1016/j.leukres.2017.05.006. Epub 2017 May 9. PubMed 28535394 ↗
  • Huemer F, Weiss L, Faber V, Neureiter D, Egle A, Geissler K, Voskova D, Zebisch A, Burgstaller S, Pichler A, Stauder R, Sperr W, Lang A, Pfeilstocker M, Machherndl-Spandl S, Stampfl M, Greil R, Pleyer L. Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wien Klin Wochenschr. 2018 Feb;130(3-4):115-125. doi: 10.1007/s00508-018-1315-2. Epub 2018 Jan 30. PubMed 29383443 ↗
  • Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int J Mol Sci. 2017 Apr 14;18(4):837. doi: 10.3390/ijms18040837. PubMed 28420120 ↗
  • Pleyer L, Dohner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstocker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. Int J Mol Sci. 2017 Feb 15;18(2):415. doi: 10.3390/ijms18020415. PubMed 28212292 ↗
  • Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Zebisch A, Pichler A, Pfeilstocker M, Autzinger EM, Lang A, Geissler K, Voskova D, Geissler D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. J Hematol Oncol. 2016 Apr 16;9:39. doi: 10.1186/s13045-016-0263-4. PubMed 27084507 ↗
  • Ramos F, Thepot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martinez-Robles V, Burgstaller S, Recher C, Deben G, Gaidano G, Gardin C, Musto P, Greil R, Sanchez-Guijo F, Fenaux P; European ALMA Investigators. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31. PubMed 25601157 ↗
  • Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, Schreder M, Tinchon C, Sliwa T, Lang A, Sperr WR, Krippl P, Geissler D, Voskova D, Schlick K, Thaler J, Machherndl-Spandl S, Theiler G, Eckmullner O, Greil R. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol. 2014 Nov;93(11):1825-38. doi: 10.1007/s00277-014-2126-9. Epub 2014 Jun 21. PubMed 24951123 ↗
  • Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, Girschikofsky M, Schreder M, Pfeilstocker M, Lang A, Sliwa T, Geissler D, Schlick K, Placher-Sorko G, Theiler G, Thaler J, Mitrovic M, Neureiter D, Valent P, Greil R. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014 Apr;38(4):475-83. doi: 10.1016/j.leukres.2014.01.006. Epub 2014 Jan 18. PubMed 24522248 ↗
  • Melchardt T, Weiss L, Pleyer L, Steinkirchner S, Auberger J, Hopfinger G, Greil R, Egle A. Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome. Oncol Lett. 2013 Dec;6(6):1756-1758. doi: 10.3892/ol.2013.1629. Epub 2013 Oct 15. PubMed 24260071 ↗
  • Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M, Lang A, Krippl P, Sliwa T, Egle A, Linkesch W, Voskova D, Angermann H, Greil R. Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol. 2013 Apr 29;6:32. doi: 10.1186/1756-8722-6-32. PubMed 23627920 ↗
  • Valentiny C, Mitrovic M, Pleyer L, Steurer M, Willenbacher W, Stauder R. Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia. Wien Klin Wochenschr. 2013 Jan;125(1-2):50-3. doi: 10.1007/s00508-012-0319-6. Epub 2013 Jan 5. PubMed 23292646 ↗
  • Weiss L, Melchardt T, Neureiter D, Kemmerling R, Moshir S, Pleyer L, Greil R, Egle A. Complete remission of Waldenstrom macroglobulinemia with azacitidine and rituximab. J Clin Oncol. 2011 Aug 20;29(24):e696-8. doi: 10.1200/JCO.2011.35.8283. Epub 2011 Jul 5. No abstract available. PubMed 21730268 ↗
  • Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Munoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortes A, Avendano Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021 Feb;8(2):e135-e148. doi: 10.1016/S2352-3026(20)30374-4. PubMed 33513373 ↗
  • Leisch M, Pfeilstocker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Tinchon C, Hartmann B, Petzer A, Schreder M, Kiesl D, Vallet S, Egle A, Melchardt T, Piringer G, Zebisch A, Machherndl-Spandl S, Wolf D, Keil F, Drost M, Greil R, Pleyer L. Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group. Cancers (Basel). 2022 May 17;14(10):2459. doi: 10.3390/cancers14102459. PubMed 35626063 ↗
  • Pleyer L, Sekeres MA. An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes. Lancet Haematol. 2022 Oct;9(10):e714-e716. doi: 10.1016/S2352-3026(22)00252-6. Epub 2022 Sep 2. No abstract available. PubMed 36063831 ↗
  • Pleyer L, Heibl S, Tinchon C, Vallet S, Schreder M, Melchardt T, Stute N, Fohrenbach Quiroz KT, Leisch M, Egle A, Scagnetti L, Wolf D, Beswick R, Drost M, Larcher-Senn J, Grochtdreis T, Vaisband M, Hasenauer J, Zaborsky N, Greil R, Stauder R. Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT. Cancers (Basel). 2023 Feb 22;15(5):1388. doi: 10.3390/cancers15051388. PubMed 36900181 ↗
  • Jansko-Gadermeir B, Leisch M, Gassner FJ, Zaborsky N, Dillinger T, Hutter S, Risch A, Melchardt T, Egle A, Drost M, Larcher-Senn J, Greil R, Pleyer L. Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group. Cancers (Basel). 2023 Apr 14;15(8):2305. doi: 10.3390/cancers15082305. PubMed 37190237 ↗
  • Pleyer L, Vaisband M, Drost M, Pfeilstocker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Pichler A, Hartmann B, Petzer A, Schreder M, Schmitt CA, Vallet S, Melchardt T, Zebisch A, Pichler P, Zaborsky N, Machherndl-Spandl S, Wolf D, Keil F, Hasenauer J, Larcher-Senn J, Greil R. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT. Am J Hematol. 2023 Nov;98(11):1685-1698. doi: 10.1002/ajh.27046. Epub 2023 Aug 7. PubMed 37548390 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Apr 2029, 105 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2020
First posted
Jun 19, 2020
StartActual
Jul 13, 2020
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2030
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04438889
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Jul 13, 2020
Primary completion
Apr 2029 (estimated)
Completion
Apr 2030 (estimated)
Last update
Apr 10, 2025

Study contacts

Lisa Pleyer, MD
Contact
dr.lisa.pleyer@gmail.com
+43676899758271
Daniela Wolkersdorfer
Contact
office@agmt.at
+436626404412
Richard Greil, MD
study chair · AGMT gemeinnützige GmbH
Lisa Pleyer, MD
principal investigator · 3rd Med Dept Paracelsus Medical University, Salzburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion